NEW INVESTMENT BY FARMITALIA
Farmitalia Carlo Erba of Italy has been expanding its plant at Ascoli Piceno in the south of the country. The plant accounts for 30% of Farmitalia sales, which were 1,389 billion lire ($906.1 million) in 1991. The plant was established in 1972 with the help of regional financial aid.
A new unit covering 4,000 m2 has now been added to the 1972 unit of 16,000m2. The plant makes extensive use of automation technology in drug production but the workforce has actually increased from 130 to 300. Ascoli has now become Farmitalia's second major center for non-parenteral forms of drug output alongside the plant at Nerviano. Sales from Ascoli have expanded steadily and some 10 billion lire of new investment will be put in by the company over the next two years.
Output has been increased from 25 to 60 million units annually, and production capacity is now over 80 million units.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze